UCB And Biogen Idec's Oral VLA-4 Antagonist (CDP323) Enters Phase II Development For Multiple Sclerosis
Medical News Today Sat, 30 Jun 2007 1:08 AM PDT
UCB (Euronext Brussels: UCB) and Biogen Idec (NASDAQ: BIIB) yesterday announced the initiation of a Phase II study of CDP323 - an oral VLA-4 antagonist - under development for relapsing-remitting multiple sclerosis (MS). The double-blind, randomized Phase II study commenced this week with dosing of the first patient. [click link for full article]